Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium‐111 capromab pendetide

Optimum therapy for prostate carcinoma patients requires accurate staging, but computed tomography (CT) and magnetic resonance imaging (MRI) have limitations as methods for detecting soft tissue metastases. In this study, radioimmunoscintigraphy (RIS) was evaluated for its ability to identify sites of metastatic disease in lymph nodes.

[1]  P. Walsh,et al.  Evaluation of transrectal ultrasound in the early detection of prostate cancer. , 1989, The Journal of urology.

[2]  K. Burnett,et al.  Radioimmunodetection of cancer with the use of indium-111-labeled monoclonal antibodies. , 1987, NCI monographs : a publication of the National Cancer Institute.

[3]  R. Babaian,et al.  Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356. , 1994, The Journal of urology.

[4]  W. L. Davis,et al.  Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. , 1990, Cancer research.

[5]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[6]  Richard D. Williams,et al.  Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Petrylak,et al.  Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer. , 1992, Seminars in urology.

[8]  Burgers Jk,et al.  Monoclonal antibody imaging of recurrent and metastatic prostate cancer. , 1995 .

[9]  G. Murphy,et al.  Immunoscintigraphy of prostatic cancer: Preliminary results with 111in‐labeled monoclonal antibody 7E11‐C5.3 (CYT‐356) , 1991, The Prostate.

[10]  H. Forman,et al.  Neoplasms of the bladder, prostate, and testis. , 1994, Radiologic clinics of North America.

[11]  R B Jeffrey,et al.  Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. , 1987, Radiology.

[12]  R. Maguire,et al.  Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site‐specific immunoconjugates , 1993 .

[13]  D. Krag,et al.  Radiolabeled Antibody Imaging in the Management of Colorectal Cancer Results of a Multicenter Clinical Study , 1991, Annals of surgery.

[14]  G. Hinkle,et al.  Monoclonal antibody imaging of recurrent and metastatic prostate cancer. , 1995, Seminars in urology.

[15]  P. Wingo,et al.  Cancer statistics, 1997 , 1997, CA: a cancer journal for clinicians.

[16]  S. Golding,et al.  Patterns of lymphatic metastases at recurrence of prostate cancer: CT findings. , 1994, Clinical radiology.

[17]  W. Catalona,et al.  Staging errors in clinically localized prostatic cancer. , 1982, The Journal of urology.

[18]  J. W. Mcroberts,et al.  Radioimmunodetection of prostatic cancer. In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging. , 1983, JAMA.

[19]  R. Babaian,et al.  Radioimmunoscintigraphy for prostate cancer. , 1989, Tecnologica. MAP supplement. Blue Cross and Blue Shield Association. Medical Advisory Panel.

[20]  R. Bahnson,et al.  Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. , 1996, Clinical nuclear medicine.

[21]  K. Yoshida,et al.  Two different lymph node metastatic patterns of a prostatic cancer , 1990, Cancer.

[22]  R. Dreicer,et al.  Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. , 1994, The Journal of urology.

[23]  G. Murphy,et al.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. , 1987, Anticancer research.

[24]  J. Mohler,et al.  Preoperative prediction of pathological tumor volume and stage in clinically localized prostate cancer: comparison of digital rectal examination, transrectal ultrasonography and magnetic resonance imaging. , 1991, The Journal of urology.